Impax Asset Management Group plc Sells 6,320 Shares of Illumina, Inc. (NASDAQ:ILMN)

Impax Asset Management Group plc cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 57,653 shares of the life sciences company’s stock after selling 6,320 shares during the period. Impax Asset Management Group plc’s holdings in Illumina were worth $7,704,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Golden State Wealth Management LLC bought a new position in Illumina in the 4th quarter worth approximately $32,000. Versant Capital Management Inc boosted its holdings in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the period. TD Private Client Wealth LLC boosted its holdings in Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares during the period. V Square Quantitative Management LLC boosted its holdings in Illumina by 50.6% in the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 132 shares during the period. Finally, First Horizon Advisors Inc. boosted its holdings in Illumina by 73.5% in the 4th quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock valued at $59,000 after purchasing an additional 186 shares during the period. 89.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Robert W. Baird raised their price target on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Barclays downgraded shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price target for the company from $130.00 to $100.00 in a report on Monday, February 10th. UBS Group raised their price target on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Royal Bank of Canada cut their price target on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, Piper Sandler raised their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $159.45.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $93.96 on Tuesday. The stock has a market cap of $14.88 billion, a PE ratio of -12.23, a PEG ratio of 1.60 and a beta of 1.10. The company’s fifty day moving average is $126.97 and its 200 day moving average is $133.99. Illumina, Inc. has a 52 week low of $92.20 and a 52 week high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.